Download PDF
J Reconstr Microsurg
DOI: 10.1055/a-2483-5277
Original Article

Efficacy and Safety of Subcutaneous Unfractionated Heparin Administered Every 8 hours for Venous Thromboembolism Prophylaxis in Reconstructive Head and Neck Tumor Patients: A Systematic Review and 6-Year Institutional Case Series

Jevan Cevik 
1   Plastic and Reconstructive Surgery Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia
,
David P. Newland
1   Plastic and Reconstructive Surgery Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia
,
Edward Cheong
1   Plastic and Reconstructive Surgery Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia
,
Miguel Cabalag
1   Plastic and Reconstructive Surgery Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia
2   Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia
,
Anand Ramakrishnan 
1   Plastic and Reconstructive Surgery Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia
2   Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Patients with head and neck tumors undergoing free flap reconstructions are at high risk of postoperative venous thromboembolism (VTE). To date, no specific guidelines are available regarding VTE prophylaxis in this patient group. This study aims to contribute to this scarcity of information by reviewing the literature regarding anticoagulation regimens in this patient group and evaluating the efficacy and safety of postoperative subcutaneous heparin dosed at 5,000 units every 8 hours routinely utilized at our institution.

Methods PubMed and Embase databases were searched from inception until November 2023. Data were collected and levels of evidence were evaluated according to the Oxford Centre for Evidence Based Medicine guidelines. Additionally, a retrospective review of all patients with head and neck tumors undergoing free tissue transfer at our institution between 2015 and 2021 was performed. Patients were restricted to those receiving 5,000 units of subcutaneous heparin every 8 hours postoperatively. Key outcomes included rates of VTE and surgical site hematoma.

Results This systematic review found 15 studies eligible for inclusion ranging from 1998 to 2023. Anticoagulation regimens were markedly heterogenous. Among the literature, VTE rates reported ranged from 0 to 9.6% and bleeding rates ranged between 3.5 and 29%. Our 6-year institutional analysis revealed 393 total patients. Overall, three episodes of VTE were identified (0.76%) consisting of one deep vein thrombosis and two pulmonary emboli. The overall rate of hematoma was 9.4% with a higher rate of hematoma at the recipient site (8.1%) than the donor site (1.3%).

Conclusion When compared with the existing literature this study found a low rate of VTE and a comparable incidence postoperative hematoma. This suggests that 5,000 units of subcutaneous heparin given every 8 hours may be a safe and effective postoperative anticoagulation regimen for these patients.

Keywords

anticoagulation - free flap - hematoma - head and neck cancer - venous thromboembolism


Publication History

Received: 07 February 2024

Accepted: 10 November 2024

Accepted Manuscript online:
25 November 2024

Article published online:
26 December 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Behranwala KA, Williamson RC. Cancer-associated venous thrombosis in the surgical setting. Ann Surg 2009; 249 (03) 366-375
    CrossrefPubMedSearch in Google Scholar
  • 2 Levine MN, Lee AY. Treatment of venous thrombosis in the cancer patient. Acta Haematol 2001; 106 (1-2): 81-87
    CrossrefPubMedSearch in Google Scholar
  • 3 Levitan N, Dowlati A, Remick SC. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78 (05) 285-291
    CrossrefPubMedSearch in Google Scholar
  • 4 Gould MK, Garcia DA, Wren SM. et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (02) e227S-e277S
    CrossrefPubMedSearch in Google Scholar
  • 5 Bahl V, Shuman AG, Hu HM. et al. Chemoprophylaxis for venous thromboembolism in otolaryngology. JAMA Otolaryngol Head Neck Surg 2014; 140 (11) 999-1005
    CrossrefPubMedSearch in Google Scholar
  • 6 Cramer JD, Dilger AE, Schneider A, Smith SS, Samant S, Patel UA. Risk of venous thromboembolism among otolaryngology patients vs general surgery and plastic surgery patients. JAMA Otolaryngol Head Neck Surg 2018; 144 (01) 9-17
    PubMedSearch in Google Scholar
  • 7 Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331 (24) 1630-1641
    CrossrefPubMedSearch in Google Scholar
  • 8 Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation 2004; 110 (24, Suppl 1): IV4-IV12
    CrossrefPubMedSearch in Google Scholar
  • 9 Cevik J, Middleton R, Ramakrishnan A, Cabalag M. Rationalizing post-operative prophylactic anticoagulation in reconstructive head and neck cancer patients: a review. ANZ J Surg 2021; 91 (12) 2610-2616
    CrossrefPubMedSearch in Google Scholar
  • 10 Venkatesh KP, Ambani SW, Arakelians ARL, Johnson JT, Solari MG. Head and neck microsurgeon practice patterns and perceptions regarding venous thromboembolism prophylaxis. J Reconstr Microsurg 2020; 36 (08) 549-555
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
    CrossrefPubMedSearch in Google Scholar
  • 12 OCEBM Levels of Evidence Working Group. “The Oxford 2011 Levels of Evidence”. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653
    PubMed
  • 13 Yue BYT, Zinn R, Roberts R, Wilson J. Use of thrombin-based haemostatic matrix in head and neck reconstructions: a potential risk factor for pulmonary embolism. ANZ J Surg 2017; 87 (12) E276-E280
    PubMedSearch in Google Scholar
  • 14 Clayburgh DR, Stott W, Cordiero T. et al. Prospective study of venous thromboembolism in patients with head and neck cancer after surgery. JAMA Otolaryngol Head Neck Surg 2013; 139 (11) 1143-1150
    CrossrefPubMedSearch in Google Scholar
  • 15 Ambani SW, Bengur FB, Varelas LJ. et al. Standard fixed enoxaparin dosing for venous thromboembolism prophylaxis leads to low peak anti-factor Xa levels in both head and neck and breast free flap patients. J Reconstr Microsurg 2022; 38 (09) 749-756
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Kakei Y, Akashi M, Hasegawa T, Minamikawa T, Usami S, Komori T. Incidence of venous thromboembolism after oral oncologic surgery with simultaneous reconstruction. J Oral Maxillofac Surg 2016; 74 (01) 212-217
    CrossrefPubMedSearch in Google Scholar
  • 17 Shuman AG, Hu HM, Pannucci CJ, Jackson CR, Bradford CR, Bahl V. Stratifying the risk of venous thromboembolism in otolaryngology. Otolaryngol Head Neck Surg 2012; 146 (05) 719-724
    CrossrefPubMedSearch in Google Scholar
  • 18 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) Advisory Panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
    CrossrefPubMedSearch in Google Scholar
  • 19 Chen CM, Disa JJ, Cordeiro PG, Pusic AL, McCarthy CM, Mehrara BJ. The incidence of venous thromboembolism after oncologic head and neck reconstruction. Ann Plast Surg 2008; 60 (05) 476-479
    CrossrefPubMedSearch in Google Scholar
  • 20 Deleyiannis FW, Clavijo-Alvarez JA, Pullikkotil B. et al. Development of consensus guidelines for venous thromboembolism prophylaxis in patients undergoing microvascular reconstruction of the mandible. Head Neck 2011; 33 (07) 1034-1040
    CrossrefPubMedSearch in Google Scholar
  • 21 Lodders JN, Parmar S, Stienen NL. et al. Incidence of symptomatic venous thromboembolism in oncological oral and maxillofacial operations: retrospective analysis. Br J Oral Maxillofac Surg 2015; 53 (03) 244-250
    CrossrefPubMedSearch in Google Scholar
  • 22 Senchenkov A, Lemaine V, Tran NV. Management of perioperative microvascular thrombotic complications - the use of multiagent anticoagulation algorithm in 395 consecutive free flaps. J Plast Reconstr Aesthet Surg 2015; 68 (09) 1293-1303
    CrossrefPubMedSearch in Google Scholar
  • 23 Sinha S, Puram SV, Sethi RK. et al. Perioperative deep vein thrombosis risk stratification. Otolaryngol Head Neck Surg 2017; 156 (01) 118-121
    CrossrefPubMedSearch in Google Scholar
  • 24 Thai L, McCarn K, Stott W. et al. Venous thromboembolism in patients with head and neck cancer after surgery. Head Neck 2013; 35 (01) 4-9
    CrossrefPubMedSearch in Google Scholar
  • 25 Moreano EH, Hutchison JL, McCulloch TM, Graham SM, Funk GF, Hoffman HT. Incidence of deep venous thrombosis and pulmonary embolism in otolaryngology-head and neck surgery. Otolaryngol Head Neck Surg 1998; 118 (06) 777-784
    CrossrefPubMedSearch in Google Scholar
  • 26 Saadoun R, Bengur FB, Moroni EA. et al. Association between venous thromboembolism rates and different prophylactic anticoagulation regimens in patients undergoing free flap reconstruction of the head and neck region. Microsurgery 2023; 43 (07) 649-656
    CrossrefPubMedSearch in Google Scholar
  • 27 Numajiri T, Sowa Y, Nishino K. et al. Use of systemic low-dose unfractionated heparin in microvascular head and neck reconstruction: influence in free-flap outcomes. J Plast Surg Hand Surg 2016; 50 (03) 135-141
    CrossrefPubMedSearch in Google Scholar
  • 28 Barton BM, Riley CA, Fitzpatrick JC, Hasney CP, Moore BA, McCoul ED. Postoperative anticoagulation after free flap reconstruction for head and neck cancer: a systematic review. Laryngoscope 2018; 128 (02) 412-421
    CrossrefPubMedSearch in Google Scholar
  • 29 Akl EA, Kahale L, Sperati F. et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev 2014; (06) CD009447
    PubMedSearch in Google Scholar
  • 30 ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84 (08) 1099-1103
    CrossrefPubMedSearch in Google Scholar
  • 31 McLeod RS, Geerts WH, Sniderman KW. et al; Canadian Colorectal Surgery DVT Prophylaxis Trial investigators. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg 2001; 233 (03) 438-444
    CrossrefPubMedSearch in Google Scholar
  • 32 Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88 (07) 913-930
    CrossrefPubMedSearch in Google Scholar
  • 33 Baykal C, Al A, Demirtaş E, Ayhan A. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study. Eur J Gynaecol Oncol 2001; 22 (02) 127-130
    PubMedSearch in Google Scholar
  • 34 Guo Q, Huang B, Zhao J. et al. Perioperative pharmacological thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Ann Surg 2017; 265 (06) 1087-1093
    CrossrefPubMedSearch in Google Scholar
  • 35 Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39 (05) 631-636
    CrossrefPubMedSearch in Google Scholar
  • 36 Hull RD, Raskob GE, Brant RF. et al; American-Canadian Thrombosis Study Group. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000; 160 (02) 229-236
    CrossrefPubMedSearch in Google Scholar
  • 37 Linkins LA. Heparin induced thrombocytopenia. BMJ 2015; 350: g7566
    CrossrefPubMedSearch in Google Scholar
  • 38 Bertolaccini CM, Prazak AMB, Goodwin IA. et al. Prevention of venous thromboembolism in microvascular surgery patients using weight-based unfractionated heparin infusions. J Reconstr Microsurg 2022; 38 (05) 395-401
    Thieme ConnectPubMedSearch in Google Scholar
  • 39 Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg 2010; 199 (01) S3-S10
    CrossrefPubMedSearch in Google Scholar
  • 40 Blackburn TK, Java KR, Lowe D, Brown JS, Rogers SN. Safety of a regimen for thromboprophylaxis in head and neck cancer microvascular reconstructive surgery: non-concurrent cohort study. Br J Oral Maxillofac Surg 2012; 50 (03) 227-232
    CrossrefPubMedSearch in Google Scholar
  • 41 Tipirneni KE, Bauter L, Arnold MA, Audlin JA, Ryan J, Marzouk M. Association of prolonged-duration chemoprophylaxis with venous thromboembolism in high-risk patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 2021; 147 (04) 320-328
    CrossrefPubMedSearch in Google Scholar
  • 42 Patel R, Stokes WA, Roberts C. et al. Preoperative low-molecular weight heparin chemoprophylaxis in head and neck free flap reconstruction. Am J Otolaryngol 2023; 44 (02) 103722
    CrossrefPubMedSearch in Google Scholar
  • 43 Grill FD, Pilstl L, Ritschl LM. et al. Perioperative anticoagulation in head and neck free flap reconstructions: experience of an anticoagulative scheme and its modification. Microsurgery 2024; 44 (01) e31096
    CrossrefPubMedSearch in Google Scholar